Tonglei Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8373698/publications.pdf

Version: 2024-02-01

97 papers	2,702 citations	28 h-index	205818 48 g-index
116	116	116	2979
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Polymorphism and cocrystal salt formation of 2-((2,6-dichlorophenyl)amino)benzoic acid, harvest of a second form of 2-((2,6-dimethylphenyl)amino)benzoic acid, and isomorphism between the two systems. CrystEngComm, 2022, 24, 681-690.	1.3	5
2	pH-dependent oiling-out during the polymorph transformation of disodium guanosine 5′-monophosphate. CrystEngComm, 2022, 24, 1630-1637.	1.3	3
3	Biodistribution and Non-linear Gene Expression of mRNA LNPs Affected by Delivery Route and Particle Size. Pharmaceutical Research, 2022, 39, 105-114.	1.7	48
4	Paclitaxel Drug Delivery Systems: Focus on Nanocrystals' Surface Modifications. Polymers, 2022, 14, 658.	2.0	23
5	Understanding Formulation and Temperature Effects on Dermal Transport Kinetics by IVPT and Multiphysics Simulation. Pharmaceutical Research, 2022, 39, 893-905.	1.7	3
6	Kinetic Retraction at the Onset of Concomitant Crystallization and Implication on Polymorphic Formation. Molecular Pharmaceutics, 2022, 19, 2676-2680.	2.3	4
7	Probing Molecular Packing of Drug Substances in Nanometer Domains in Pharmaceutical Formulations Using ¹⁹ F Magic Angle Spinning NMR. Journal of Physical Chemistry C, 2022, 126, 12025-12037.	1.5	4
8	Intracellular uptake of nanocrystals: Probing with aggregation-induced emission of fluorescence and kinetic modeling. Acta Pharmaceutica Sinica B, 2021, 11, 1021-1029.	5.7	15
9	Form selection of concomitant polymorphs: A case study informed by crystallization kinetics modeling. AICHE Journal, 2021, 67, e17129.	1.8	18
10	A new solvate of clonixin and a comparison of the two clonixin solvates. RSC Advances, 2021, 11, 24836-24842.	1.7	3
11	Nanoparticle-Mediated Cytoplasmic Delivery of MessengerÂRNA Vaccines: Challenges and Future Perspectives. Pharmaceutical Research, 2021, 38, 473-478.	1.7	63
12	Editorial of Special Issue "The Biological Fate of Drug Nanocarriers― Acta Pharmaceutica Sinica B, 2021, 11, 850-851.	5.7	9
13	Multiphysics Modeling and Simulation of Subcutaneous Injection and Absorption of Biotherapeutics: Model Development. Pharmaceutical Research, 2021, 38, 607-624.	1.7	14
14	Preferential Oxycodone Loss of Physically Manipulated Abuse Deterrent Oxycodone HCl Extended Release Tablets Prepared for Nasal Insufflation Studies. Pharmaceutical Research, 2021, 38, 1263-1278.	1.7	2
15	Multiphysics Modeling and Simulation of Subcutaneous Injection and Absorption of Biotherapeutics: Sensitivity Analysis. Pharmaceutical Research, 2021, 38, 1011-1030.	1.7	15
16	Multiscale pharmacokinetic modeling of systemic exposure of subcutaneously injected biotherapeutics. Journal of Controlled Release, 2021, 337, 407-416.	4.8	13
17	Challenges Ahead. Pharmaceutical Research, 2021, 38, 1-1.	1.7	1
18	Synthon Polymorphism and π–π Stacking in <i>N</i> -Phenyl-2-hydroxynicotinanilides. Crystal Growth and Design, 2021, 21, 6155-6165.	1.4	9

#	Article	IF	Citations
19	Double substitution leads to a highly polymorphic system in 5-methyl-2-m-tolylamino-benzoic acid. CrystEngComm, 2021, 24, 95-106.	1.3	4
20	Evaluation of intestinal permeation enhancement with carboxymethyl chitosan-rhein polymeric micelles for oral delivery of paclitaxel. International Journal of Pharmaceutics, 2020, 573, 118840.	2.6	18
21	An investigation of the polymorphism of a potent nonsteroidal anti-inflammatory drug flunixin. CrystEngComm, 2020, 22, 448-457.	1.3	6
22	Big Shoes to Fill at A Challenging Time. Pharmaceutical Research, 2020, 37, 154.	1.7	0
23	Steric Effect Determines the Formation of Lactam–Lactam Dimers or Amide Câ•O···NH (Lactam) Chain Motifs in <i>N</i> -Phenyl-2-hydroxynicotinanilides. Crystal Growth and Design, 2020, 20, 4346-4357.	1.4	5
24	Kinetic Difference between Concomitant Polymorphism and Solvent-Mediated Phase Transformation: A Case of Tolfenamic Acid. Crystal Growth and Design, 2020, 20, 1779-1788.	1.4	21
25	Delivering anticancer drugs as carrier-free nanocrystals. , 2020, , 95-115.		0
26	Development of carrier-free nanocrystals of poorly water-soluble drugs by exploring metastable zone of nucleation. Acta Pharmaceutica Sinica B, 2019, 9, 118-127.	5.7	42
27	Locality and strength of intermolecular interactions in organic crystals: using conceptual density functional theory (CDFT) to characterize a highly polymorphic system. Theoretical Chemistry Accounts, 2019, 138, 1.	0.5	3
28	Unraveling the in vivo fate and cellular pharmacokinetics of drug nanocarriers. Advanced Drug Delivery Reviews, 2019, 143, 1-2.	6.6	23
29	Local Concentrating, Not Shear Stress, That May Lead to Possible Instability of Protein Molecules During Syringe Injection: A Fluid Dynamic Study with Two-Phase Flow Model. PDA Journal of Pharmaceutical Science and Technology, 2019, 73, 260-275.	0.3	12
30	Hybrid drug nanocrystals. Advanced Drug Delivery Reviews, 2019, 143, 115-133.	6.6	79
31	Effect of Substituent Size and Isomerization on the Polymorphism of 2-(Naphthalenylamino)-benzoic Acids. Crystal Growth and Design, 2019, 19, 3694-3703.	1.4	6
32	Solid-State Characterization of Three Polymorphs of an Orally Available Analog of Diethylenetriaminepentaacetic Acid. AAPS PharmSciTech, 2019, 20, 8.	1.5	1
33	Formulation and Manufacturing of Solid Dosage Forms. Pharmaceutical Research, 2019, 36, 16.	1.7	7
34	Preparation and evaluation of carboxymethyl chitosan-rhein polymeric micelles with synergistic antitumor effect for oral delivery of paclitaxel. Carbohydrate Polymers, 2019, 206, 121-131.	5.1	52
35	Preparation and characterization of multimodal hybrid organic and inorganic nanocrystals of camptothecin and gold. Acta Pharmaceutica Sinica B, 2019, 9, 128-134.	5.7	8
36	Exploring Molecular Speciation and Crystallization Mechanism of Amorphous 2-Phenylamino Nicotinic Acid. Pharmaceutical Research, 2018, 35, 51.	1.7	6

#	Article	IF	CITATIONS
37	Gaining Thermodynamic Insight From Distinct Glass Formation Kinetics of Structurally Similar Organic Compounds. Journal of Pharmaceutical Sciences, 2018, 107, 192-202.	1.6	6
38	Crystal packing and crystallization tendency from the melt of 2-((2-ethylphenyl)amino)nicotinic acid. Zeitschrift Fur Kristallographie - Crystalline Materials, 2018, 233, 9-16.	0.4	5
39	Epithelia transmembrane transport of orally administered ultrafine drug particles evidenced by environment sensitive fluorophores in cellular and animal studies. Journal of Controlled Release, 2018, 270, 65-75.	4.8	59
40	Zwitterion formation and subsequent carboxylate–pyridinium NH synthon generation through isomerization of 2-anilinonicotinic acid. CrystEngComm, 2018, 20, 6126-6132.	1.3	1
41	Peptidomimicry with C ₂ â€Symmetric Oligourea Derivatives of 1,2â€Diaminocyclohexane and 1,2â€Diphenylâ€1,2â€diaminoethane: Chirality and Chain Lengthâ€Dependent Conformation. ChemistrySelect, 2018, 3, 11035-11041.	0.7	O
42	Substituent Electronegativity and Isostructurality in the Polymorphism of Clonixin Analogues. Crystal Growth and Design, 2018, 18, 7006-7014.	1.4	8
43	Structural Isomerization of 2-Anilinonicotinic Acid Leads to a New Synthon in 6-Anilinonicotinic Acids. Crystal Growth and Design, 2018, 18, 4849-4859.	1.4	3
44	Impact of Supramolecular Aggregation on the Crystallization Kinetics of Organic Compounds from the Supercooled Liquid State. Molecular Pharmaceutics, 2017, 14, 2126-2137.	2.3	10
45	Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities. Acta Pharmacologica Sinica, 2017, 38, 782-797.	2.8	196
46	Strong Hydrogen Bond Leads to a Fifth Crystalline Form and Polymorphism of Clonixin. ChemistrySelect, 2017, 2, 4942-4950.	0.7	15
47	Effects of Coating Materials and Processing Conditions on Flow Enhancement of Cohesive Acetaminophen Powders by High-Shear Processing With Pharmaceutical Lubricants. Journal of Pharmaceutical Sciences, 2017, 106, 3022-3032.	1.6	13
48	Integrating <i>In Vitro </i> , Modeling, and <i>In Vivo </i> Approaches to Investigate Warfarin Bioequivalence. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 523-531.	1.3	22
49	Persistent Self-Association of Solute Molecules in Solution. Journal of Physical Chemistry B, 2017, 121, 10118-10124.	1.2	38
50	Exploring intracellular fate of drug nanocrystals with crystal-integrated and environment-sensitive fluorophores. Journal of Controlled Release, 2017, 267, 214-222.	4.8	36
51	Glycine's pH-Dependent Polymorphism: A Perspective from Self-Association in Solution. Crystal Growth and Design, 2017, 17, 5028-5033.	1.4	26
52	Higher-Order Self-Assembly of Benzoic Acid in Solution. Crystal Growth and Design, 2017, 17, 5049-5053.	1.4	27
53	^{sp2} CHâ<-Cl hydrogen bond in the conformational polymorphism of 4-chloro-phenylanthranilic acid. CrystEngComm, 2017, 19, 4345-4354.	1.3	18
54	Tautomeric Polymorphism of 4-Hydroxynicotinic Acid. Crystal Growth and Design, 2016, 16, 2573-2580.	1.4	23

#	Article	IF	Citations
55	Solid-State Spectroscopic Investigation of Molecular Interactions between Clofazimine and Hypromellose Phthalate in Amorphous Solid Dispersions. Molecular Pharmaceutics, 2016, 13, 3964-3975.	2.3	69
56	Impact of surfactant treatment of paclitaxel nanocrystals on biodistribution and tumor accumulation in tumor-bearing mice. Journal of Controlled Release, 2016, 237, 168-176.	4.8	40
57	Polymorphism and solid-to-solid phase transitions of a simple organic molecule, 3-chloroisonicotinic acid. CrystEngComm, 2015, 17, 2389-2397.	1.3	15
58	Solid-state identity of 2-hydroxynicotinic acid and its polymorphism. CrystEngComm, 2015, 17, 5195-5205.	1.3	19
59	Cellular Uptake Mechanism of Paclitaxel Nanocrystals Determined by Confocal Imaging and Kinetic Measurement. AAPS Journal, 2015, 17, 1126-1134.	2.2	41
60	Reactivity of triacetone triperoxide and diacetone diperoxide: Insights from nuclear Fukui function. Frontiers of Chemical Science and Engineering, 2015, 9, 114-123.	2.3	4
61	Developing nanocrystals for cancer treatment. Nanomedicine, 2015, 10, 2537-2552.	1.7	104
62	From Competition to Commensuration by Two Major Hydrogen-Bonding Motifs. Crystal Growth and Design, 2014, 14, 27-31.	1.4	19
63	Pharmacokinetics and Treatment Efficacy of Camptothecin Nanocrystals on Lung Metastasis. Molecular Pharmaceutics, 2014, 11, 226-233.	2.3	29
64	Intermolecular interactions in organic crystals: gaining insight from electronic structure analysis by density functional theory. CrystEngComm, 2014, 16, 7162-7171.	1.3	10
65	Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation. Journal of Controlled Release, 2014, 176, 76-85.	4.8	94
66	Nucleation of Conformational Polymorphs: A Computational Study of Tolfenamic Acid by Explicit Solvation. Crystal Growth and Design, 2014, 14, 2709-2713.	1.4	24
67	In Vivo Investigation of Hybrid Paclitaxel Nanocrystals with Dual Fluorescent Probes for Cancer Theranostics. Pharmaceutical Research, 2014, 31, 1450-1459.	1.7	49
68	Two Major Pre-Nucleation Species that are Conformationally Distinct and in Equilibrium of Self-Association. Crystal Growth and Design, 2013, 13, 3303-3307.	1.4	24
69	Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: Lessons learned of the EPR effect and image-guided drug delivery. Journal of Controlled Release, 2013, 172, 12-21.	4.8	168
70	Polymorph Formation and Nucleation Mechanism of Tolfenamic Acid in Solution: An Investigation of Pre-nucleation Solute Association. Pharmaceutical Research, 2012, 29, 460-470.	1.7	62
71	Electronic origin of pyridinyl N as a better hydrogen-bonding acceptor than carbonyl O. CrystEngComm, 2011, 13, 6356.	1.3	25
72	Hybrid Nanocrystals: Achieving Concurrent Therapeutic and Bioimaging Functionalities toward Solid Tumors. Molecular Pharmaceutics, 2011, 8, 1985-1991.	2.3	68

#	Article	IF	CITATIONS
73	Interplay between molecular conformation and intermolecular interactions in conformational polymorphism: A molecular perspective from electronic calculations of tolfenamic acid. International Journal of Pharmaceutics, 2011, 418, 179-186.	2.6	25
74	Phase Transition from Two $\langle i \rangle Z \langle i \rangle \hat{a} \in ^2$ = 1 Forms to a $\langle i \rangle Z \langle i \rangle \hat{a} \in ^2$ = 2 Form of a Concomitant Conformational Polymorphic System. Crystal Growth and Design, 2011, 11, 414-421.	1.4	25
75	Preparation and antitumor study of camptothecin nanocrystals. International Journal of Pharmaceutics, 2011, 415, 293-300.	2.6	124
76	Enforcing Molecule's Ï€-Conjugation and Consequent Formation of the Acidâ^'Acid Homosynthon over the Acidâ^'Pyridine Heterosynthon in 2-Anilinonicotinic Acids. Crystal Growth and Design, 2010, 10, 2465-2469.	1.4	25
77	Controlled Formation of the Acidâ^'Pyridine Heterosynthon over the Acidâ^'Acid Homosynthon in 2-Anilinonicotinic Acids. Crystal Growth and Design, 2009, 9, 4993-4997.	1.4	34
78	Polymorphism of an Organic System Effected by the Directionality of Hydrogen-Bonding Chains. Crystal Growth and Design, 2008, 8, 3137-3140.	1.4	29
79	Polymorphism and Phase Behaviors of 2-(Phenylamino)nicotinic Acid. Crystal Growth and Design, 2008, 8, 4006-4013.	1.4	49
80	6-Oxo-1,6-dihydropyridine-3-carboxylic acid. Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o2784-o2784.	0.2	7
81	N-(3-Chloro-2-methylphenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide. Acta Crystallographica Section E: Structure Reports Online, 2006, 62, o4278-o4279.	0.2	4
82	Predicting Lattice Energy of Organic Crystals by Density Functional Theory with Empirically Corrected Dispersion Energy. Journal of Chemical Theory and Computation, 2006, 2, 149-156.	2.3	94
83	Empirically Augmented Density Functional Theory for Predicting Lattice Energies of Aspirin, Acetaminophen Polymorphs, and Ibuprofen Homochiral and Racemic Crystals. Pharmaceutical Research, 2006, 23, 2326-2332.	1.7	42
84	Dissolution Study on Aspirin and \hat{l} ±-Glycine Crystals. Journal of Physical Chemistry B, 2004, 108, 11219-11227.	1.2	24
85	A statistical support for using spectroscopic methods to validate the content uniformity of solid dosage forms. Journal of Pharmaceutical Sciences, 2003, 92, 1526-1530.	1.6	17
86	Understanding the Formation of Etching Patterns Using a Refined Monte Carlo Simulation Model. Crystal Growth and Design, 2002, 2, 177-184.	1.4	6
87	Crystal Packing and Chemical Reactivity of Two Polymorphs of Flufenamic Acid with Ammonia. Molecular Crystals and Liquid Crystals, 2002, 381, 121-131.	0.4	19
88	How Specific Interactions between Acetaminophen and Its Additive 4-Methylacetanilide Affect Growth Morphology:  Elucidation Using Etching Patterns. Crystal Growth and Design, 2002, 2, 185-189.	1.4	9
89	Title is missing!. Pharmaceutical Research, 2000, 17, 1439-1442.	1.7	0
90	Biocatalytic Synthesis of Vanillin. Applied and Environmental Microbiology, 2000, 66, 684-687.	1.4	87

Tonglei Li

#	Article	IF	CITATION
91	Production and Analysis of High Resolution Polymer Replicas of Fibrillar Collagen. Microscopy and Microanalysis, 1999, 5, 398-399.	0.2	0
92	Fractal analysis of pharmaceutical particles by atomic force microscopy. Pharmaceutical Research, 1998, 15, 1222-1232.	1.7	30
93	NMR Identification of an Acyl-adenylate Intermediate in the Aryl-aldehyde Oxidoreductase Catalyzed Reaction. Journal of Biological Chemistry, 1998, 273, 34230-34233.	1.6	18
94	Comparative stereochemical analysis of glucose-binding proteins for rational design of glucose-specific agents. Journal of Biomaterials Science, Polymer Edition, 1998, 9, 327-344.	1.9	21
95	AFM and Fractal Analysis of Biomaterial Microtopography. Microscopy and Microanalysis, 1998, 4, 926-927.	0.2	1
96	Purification, characterization, and properties of an aryl aldehyde oxidoreductase from Nocardia sp. strain NRRL 5646. Journal of Bacteriology, 1997, 179, 3482-3487.	1.0	68
97	Conformational flexibility and substitution pattern lead to polymorphism of 3-methyl-2-(phenylamino)benzoic acid. CrystEngComm, 0, , .	1.3	2